Dan Barnes examines how buy-side firms are planning to adapt their businesses in the face of the new OTC regulation.
Buy-side firms are reshaping their operations to cope
with the effects of OTC derivatives regulation, finds Dan
As regulators transpose G20 policies into legislation,
strengthening the global over-the-counter derivatives market,
fund managers are being asked to do more work per trade,
forcing them to make either big internal investments or to use
third-party providers for support.
"There's always a cost burden to regulatory compliance
and it is one of the more challenging factors of doing
business," says Matt Nelson executive director of strategy at
post-trade technology provider Omgeo.
"For money managers and for hedge fund managers, the
cost of compliance can never improve the top line; it can never
help you book in revenue."
This article is available to subscribers and registered users
Please log in to continue reading.
Not yet registered? Take a free trial.
If you have already taken a free trial you
have ongoing access to the analysis section of FOW.com including this story.
Log in using your details below to read.
Already have an account? |